Organisation paid for research Program year 2025 Source: CMS Open Payments

Stanford Cancer Ctr

Neither a doctor nor a teaching hospital

Research payments

$2,582,986

978 payments

Through program year 2025, Stanford Cancer Ctr is reported as receiving $2,582,986 in research payments, across 978 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$1,855,804	659
2024	Research	$300,949	74
2023	Research	$223,196	89
2022	Research	$31,165	40
2021	Research	$170,878	88
2019	Research	$994	28

Breakdown

Who paid Research payments · program years 2019–2025

Incyte Corporation $2,582,986 978 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 1, Open-Label, Multicenter Study of INCA033989 in Participants With Myeloproliferative Neoplasms $640,044 341 payments
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation $487,017 105 payments
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms $447,905 118 payments
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma $366,305 85 payments
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) $160,645 82 payments
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders $154,825 53 payments
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms. $62,214 20 payments
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma $60,284 23 payments
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease $49,252 20 payments
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders $42,890 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.